PLUR logo

PLURI INC

PLURNASDAQ
🏆 #4941 by market capUS Equity
$1.06▼ $0.02 (−1.85%)
After hours · at close
🔔
Track PLUR
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 1.9%
7d▲ 0.0%
14d▼ 17.8%
30d▼ 30.7%
ytd▼ 64.8%
1y▼ 77.4%
🏦Market Cap
$11M
Small Cap
📈Revenue Growth (YoY)
-20.9%
Declining
📊Gross Margin
40.2%
Healthy
💵FCF Margin
—
⚖️P/S Ratio
99.6x
Expensive
Otter Score
64
Fair

Trading Snapshot

Day Range
$1.05 – $1.07
52-Week Range
$0.98 – $4.87
Volume
$2.87B
Avg Volume
$3.01B
Shares Outstanding
10.8M
Next Earnings
Nov 2, 2026

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$335,000
P/E Ratio
—
P/S Ratio
99.6x
EPS (TTM)
$-2.46
Dividend Yield
—
Dilution (1yr)
+16.9%

Why Investors Own PLUR

  • ✓High-growth profile — revenue up +9.0% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 33% gross margin and 11% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PLUR logo

PLURI INC

PLUR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1M▼ −24.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
44.6%▼ −8.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$25M▲ +12.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$20M▲ +2.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
10.8M▲ +16.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$31M▲ +$4M YoY
StockOtter · stockotter.space

About PLURI INC

Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Price Target

ⓘ
Average Target
$1.14
▲ +7.3% Upside
High Target$1.30
Low Target$0.94
Based on 9 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

PLURI INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift PLUR price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

PLURI INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.